Reported about 1 month ago
Pfizer reported fourth-quarter profits that exceeded Wall Street expectations, driven by robust sales of its heart disease medication and less than anticipated decline in COVID vaccine sales. The company earned 63 cents per share, significantly above the expected 47 cents, while total revenue reached $17.76 billion, surpassing the projected $17.36 billion. Despite past success, Pfizer is under pressure from investors to demonstrate that recent acquisitions will yield returns, amidst concerns over potential revenue losses as top treatments approach patent expiration.
Source: YAHOO